

Assessment of the Emotional-Volitional Sphere in the Post-Covid Period and Treatment Tactics

Barzhakova G. R.

Bukhara State Medical Institute

ABSTRACT: Coronavirus disease-2019 (COVID-19) is a new epidemic infectious disease characterized by relatively high contagiousness and the likelihood of developing serious complications in the form of acute respiratory distress syndrome, acute respiratory and multiple organ failure. The pathogenesis of the new coronavirus infection is not sufficiently studied, it is spreading around the world for the second year. The virus is neurotropic, that is, when it enters the nervous system through olfactory receptors in the upper nasal concha, it can directly damage brain structures such as the limbic system and hypothalamus [6]. Doctors in many countries note that among the various complications after a previous illness, a significant part of patients may also develop cognitive disorders: memory, attention, concentration, or speed of thought processes [2, 4]. According to a recent non-selective survey of the US population conducted by According to the American Psychiatric Association, almost half of the respondents experience a serious level of anxiety and 40% are afraid that they or their loved ones may become seriously ill with COVID-19 and die [1, 5]. The prevalence of moderate to severe symptoms in COVID-19 *тяжелых* was as follows: anxiety-12-20%, depression-15-25%, insomnia-8% , and traumatic stress-35-49% [3]. Based on these data, emotional-volitional disorders in the post-covid period are of great interest and require the development of treatment tactics.

KEYWORD: infection, tolerance, immunity, clinic , diagnostics.

Research. The aim of the study is to study the manifestation of a violation of the emotional-volitional sphere of ah, substantiate new directions of differentiated therapeutic tactics for various manifestations of emotional-volitional disorders of ah, taking into account the dynamics of clinical and sociological parameters of the disease.

Material and methods of research. The emotional-volitional sphere in the post-covid period was studied in 46 patients. The average age of the patients was 45 years. All patients were divided into two groups: the first group received basic therapy with no tropic drugs, and the second group, in addition to basic therapy with no tropic drugs, was prescribed the antidepressant redefined (paroxetine) at a dose of 20 mg once a day for 3 months. After 3 months of YAC, the effectiveness of treatment of patients in both groups was evaluated.

Results and discussions.

Rexetin was administered at a dose of 20 mg in the morning for 30 days. Patients ' condition was assessed before taking the drug (1st visit) and after 1-5 days (2nd visit) and 30 days (3rd visit) of

261	ISSN 2690-9626 (online), Published by "Global Research Network LLC" under Volume: 3 Issue: 2 in February-2022 https://grnjournals.us/index.php/AJSHR
	Copyright (c) 2022 Author (s). This is an open-access article distributed under the terms of Creative Commons Attribution License (CC BY). To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/

treatment. To assess the effectiveness of correction of emotional and volitional spheres, we used a point scale of subjective characteristics, a personal and situational scale of anxiety and depression. Each patient was treated with a complex-individual approach. When assessing personal and situational anxiety on the scale of Spielberg-Hanin in the post-covid period, in the case of active anxiety, a high level of anxiety prevailed, and in the case of low-level anxiety, a low level of anxiety prevailed.

Table 1 Scale of personal and situational anxiety Spielberg-Hanin in the post-covid period before treatment

Type of anxiety	Low level of anxiety		Average level of anxiety		High level of anxiety	
	Abs.	%	Abs.	%	Abs.	%
Situational anxiety	12	26.1	14	30.4	20	43.5
Personal anxiety	10	21.7	24	52.2	12	26.7

After treatment, on day 30, the indicators in both groups on the scale of situational and personal anxiety and with a high level of anxiety turned into a low level of anxiety. Most patients who have had COVID-19 experienced severe asthenia, anxiety, depression, and fear of death.

Table 2 Spielberg-Hanin scale of personal and situational anxiety in the post-covid period after treatment

Type of anxiety	Low level of anxiety		Average level of anxiety		High level of anxiety	
	Abs.	%	Abs.	%	Abs.	%
Situational anxiety	26	56.5	11	23.9	9	19.6
Personal anxiety	29	63.1	9	19.5	8	17.4

Among the hospitalized patients, anxiety, confusion, depressed mood and insomnia, as well as impaired attention and memory were observed in approximately 35 %.

Table 3 Scale for assessing the level of reactive and personal anxiety Ch. D. Spielberg and Yu. L. Khanina

Patient group	The test of Ch. D. Spielberg and Yu. L. Khanin	
	Before treatment	After treatment
Comparison group	44.6,6±0.77	31.4,4±0.7*
Main group	46,5,5±0,88	19,7,7±0,55*,**

Note: - significantly compared to pretreatment $P < 0.001$; - significantly compared control $P < 0.001$

Emotional disorders led to a reduced quality of life and disrupted job security. Approximately 66.0 % of patients suffered from insomnia, and approximately 2.0% had suicidal thoughts. 50% of the patients had depression, 55% - anxiety, about 60% - psychosomatic symptoms.

Table 4 Severity of asthenic disorders in the post-covid period

Variants of the syndrome	Severity of asthenic disorders		
	Moderate symptoms	Pronounced symptoms	Total
Asthenic	4	5	9
Astheno-depressive	7	7	14

Asthenic-hysterical	3	2	5
Asthenic-obsessive	5	3	8
Astheno-hypochondriac	4	2	6
Asthenic with personality changes	3	1	4
Total	26	20	46

Clearly visible we observed an increase in asthenodynamic symptoms from 7-12 days of treatment. Against the background of these disorders, a headache appeared that had a classic "neurasthenic" color. Patients became incapable of emotional, intellectual, and physical exertion, and emotional pain increased. liability, sensitivity, tendency to react inadequately to all kinds of psycho traumatic effects. The development of asthenia and emotional tension was characterized by a cyclical pattern. More often in the morning, within 6-12 hours, against the background of severe hypothermia it emerged and quickly covered the entire emotional sphere.

According to the results of objective and subjective tests, the symptoms of emotional volitional disorders were noted as early as on the 3rd day of the disease and persisted even 30 days after treatment. Assessment of mood according to the results of the Hamilton test and asthenia (according to the Apathy and asthenia Scale) was observed in both groups. The main symptoms of asthenia were observed in patients in the form of loss of appetite-34%, restlessness-32%, unstable mood-22%, excessive excitability with subsequent exhaustion-29% and excessive fatigue-22.5%.

In the combination treatment group, the average improvement rates were higher than in the basic therapy group. According to the apathy and asthenia Scale, a significantly greater decrease in the severity of asthenia symptoms, such as absent-mindedness, mood instability, increased excitability with subsequent exhaustion, and increased fatigue was observed in the combined treatment group compared to the basic therapy group.

Table 5 QOL indicators at

Criteria quality of life	Notrop (n=32)		Notrop+ rexin(n=22)	
	day 1, day	30day	1, day	30Day 30
The overall health	of 46,7±2,3	54,6±1,3	47,4±4,6	69,7±2,3
Physical activity	45,9±3,9	52,1±3,4	46,1±3,8	70,9±3,9
the functioning of the regulation, related to the identified Phi with man's physical-standing	48,9±2,7	55,4±2,1	49,6±3,6	68,9±2,7
Functioning, connected with the emotional state	5 of 4.3±2.4 GHz	59,4±2,8	53,2±4,8	74,3±2,4
Social functioning	55,1±3,2	60,7±2,5	54,2,2±3,7	68,1±3,2
ИНТЕНСИВ Pain intensity	56,7±3,1	59,8±1,3	56,8±4,5	66,7±3,1
Vital activity	46,6±2,9	52,0±1,4	47,5±3,5	68,6±2,9
Mental health	49,5±2,8	53,5±1,2	48,3±4,4	65,5±2,8

The evaluation of the therapeutic efficacy of rexin in the post-covid period was carried out on the basis of the Hamilton scale (HDRS). When using rexin against the background of improved mood, a more pronounced regression of emotional disorders was noted. In the main group of patients, severe sedation occurred, emotional disturbances were smoothed out, and there was no increase in fear and anxiety in the evening. Along with a mild sedative effect, in the first days of treatment, rexin caused a positive trend in relation to depression. Patients became animated and made real plans for their work.

There was a significant improvement in comparison with the control group not only on the scales for assessing depression, but also on those evaluating cognitive functions. Before treatment with rexin in the main group, the severity of depressive disorder was 25.6 ± 5.4 points in the main group. By the end of the course of therapy, the average group scores on the Hamilton scale significantly improved, reaching 7.9 ± 1.3 points. In the placebo group, this dynamics was less significant: 24.4 ± 3.8 and 18.9 ± 1.7 points, respectively. In clinically stable patients with COVID-19, up to 95.6% are diagnosed with psychological problems and symptoms of stress disorders. Psychological distress in the form of depression, hopelessness, and nervousness was found in 52% of patients. Statistically significant improvement in performance was observed only after 30 days. At the time of illness, approximately 40% of patients showed neurosis-like symptoms: insomnia - 42%, impaired attention or concentration - 38%, anxiety - 36%, memory impairment - 34%, depressive disorder - 33%, confusion - 28% and altered cognition - 21%.

Conclusion. Treatment of patients who have had COVID-19 and have disorders of the emotional-volitional sphere should include correction and therapy of the emotional state, can be used in the treatment of patients who have had COVID-19 and have emotional disorders. When correcting the emotional-volitional sphere, one should use SSRI from the group – the safest and most effective class of drug for patients in this group. Patients who have had COVID-19 are a risk group due to their physiological and mental characteristics, and this infection may also be a risk factor for relapse of emotional and volitional disorders. Priority is given to early diagnosis of emotional-volitional disorders, as well as the use of pathogenesis treatment methods in combination with basic symptomatic therapy, antidepressants and nootropic drugs with proven effectiveness.

Literature

1. Mosolov S. N. "Problems of mental health in the context of the COVID-19 pandemic". S. S. Korsakov Gallery. 2020. T. 120. № 5. C. 7-15.
2. Bao Y., Sun Y., Meng S. et al. 2019-nCoV epidemic: address mental health care to empower society // Lancet. 2020. Vol. 395. P. e37-e38.
3. Lai J, Ma S, Wang Y, et al. Factors Associated With Mental Health Outcomes Among Health Care Workers Exposed to Coronavirus Disease 2019. JAMA Netw Open 2020; 3:e203976.
4. Rossi R, Socci V, Pacitti F, et al. Mental Health Outcomes Among Frontline and Second-Line Health Care Workers During the Coronavirus Disease 2019 (COVID-19) Pandemic in Italy. JAMA Netw Open 2020; 3:e2010185.
5. Schwartz BJ. New Poll: COVID-19 Impacting Mental Well-Being: Americans Feeling Anxious, Especially for Loved Ones. APA News releases. March 25, 2020.
6. The Effects of COVID-19 on Hypothalamus: Is it Another Face of SARS-CoV-2 That May Potentially Control the Level of COVID-19 Severity?. 2020.

7. Харибова Е. А., Тешаев Ш. Ж. Морфофункциональные особенности тканевой организации энтероэндокринных клеток в возрастном аспекте //Проблемы биологии и медицины. – 2020. – №. 2. – С. 168-173.
8. Харибова Е. А. Особенности морфологии нейрональных ансамблей в тройничном узле человека //Морфология. – 2011. – Т. 140. – №. 5. – С. 123-124.
9. Khodzhaeva D. I. Changes in the Vertebral Column and Thoracic Spinecells after Postponement of Mastoectomy //International Journal of Innovative Analyses and Emerging Technology. – 2021. – Т. 1. – №. 4. – С. 109-113.
10. Ilkhomovna K. D. Modern Look of Facial Skin Cancer //БарқарорликвЕтакчиТадқиқотларонлайнмийжурнали. – 2021. – Т. 1. – №. 1. – С. 85-89.
11. Ilkhomovna K. D. Morphological Features of Tumor in Different Treatment Options for Patients with Locally Advanced Breast Cancer //International Journal of Innovative Analyses and Emerging Technology. – 2021. – Т. 1. – №. 2. – С. 4-5.
12. Khodjayeve D. I. MORPHOLOGY OF IDIOPATHIC SCOLIOSIS BASED ON SEGMENT BY SEGMENT ASSESSMENT OF SPINAL COLUMN DEFORMITY //Scientific progress. – 2022. – Т. 3. – №. 1. – С. 208-215.
13. Ходжаева Д. И. СОВРЕМЕННЫЕ ВОЗМОЖНОСТИ УЛЬТРАЗВУКОВОЙ ДИАГНОСТИКИ ПРИ РАКЕ КОЖИ ЛИЦА //Жизнеобеспечение при критических состояниях. – 2019. – С. 111-112.
14. Aslonov S. G. et al. Modern Approaches to Oropharyngeal Cancer Therapy //International Journal of Discoveries and Innovations in Applied Sciences. – 2021. – Т. 1. – №. 3. – С. 38-39.
15. Khodjaeva D. I. MAGNETIC-RESONANCE IMAGING IN THE DIAGNOSIS OF BREAST CANCER AND ITS METASTASIS TO THE SPINAL COLUMN //Scientific progress. – 2021. – Т. 2. – №. 6. – С. 540-547.
16. Sadulloeva I. K., Ashurova N. G. CLINICAL AND IMMUNOLOGICAL FEATURES OF CONGENITAL HEART DEFECTS IN ADOLESCENT GIRLS //Europe's Journal of Psychology. – 2021. – Т. 17. – №. 3. – С. 172-177.
17. Kurbanovna S. I. THYMOGENIC IMMUNOCORRECTION OF CHILDREN WITH CONGENITAL HEART DEFECTS //ResearchJet Journal of Analysis and Inventions. – 2022. – Т. 3. – №. 1. – С. 34-43.
18. Kurbanovna S. I. Functioning of the Immune System in Children, After Surgical Correction of Congenital Heart Defects //European Journal of Life Safety and Stability (2660-9630). – 2021. – Т. 12. – С. 439-446.
19. Хамраева Д. Р. ЧАСТОТА РАСПРОСТРАНЕНИЯ ФУНКЦИОНАЛЬНЫХ ЗАПОРОВ У ДЕТЕЙ В БУХАРСКОЙ ОБЛАСТИ //Опыт и перспективы развития экспортного потенциала образовательных услуг в высшем образовании. – 2021. – С. 227-232.
20. Хамраева Д. Р. Частота распространения и особенности течения функциональных заболеваний билиарного тракта при синдроме Жильбера //Интернаука. Молодой исследователь: вызовы и перспективы. -2020.06. – 2020. – Т. 23. – №. 170. – С. 35-38.
21. Atoyeva M. A., Jumamuratova B. S. Psychoemotional factors related to COVID-19 quarantine //апрель-июнь. – 2021. – С. 98.

22. Atayeva M. A. Cardiomyopathy as a Manifestation of Complications of Chronic Viral Hepatitis //American Journal of Medicine and Medical Sciences. – 2020. – Т. 10. – №. 4. – С. 258-261.
23. Baratova M. S. et al. Periodontal diseases in military age persons and arterial hypertension //Asian Journal of Multidimensional Research (AJMR). – 2020. – Т. 9. – №. 4. – С. 111-113.
24. Баратова М. С., Атаева М. А. РОЛЬ ОРВИ И ГРИППА В ФОРМИРОВАНИИ ОСЛОЖНЕНИЙ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ //Редакционная коллегия. – 2018. – С. 35.
25. Жумамуратова Б. С. ИЗУЧЕНИЕ ПРИЧИНЫ СМЕРТНОСТИ ОТ COVID-19 И КЛИНИКО-ЭПИДЕМИОЛОГИЧЕСКАЯ ОЦЕНКА //Барқарорлик ва Етақчи Тадқиқотлар онлайн илмий журналі. – 2022. – Т. 2. – №. 1. – С. 390-395.
26. Achilova, D. N., et al. "Clinical, immunological and medico-social aspects of allergic diseases in children." Annals of the Romanian Society for Cell Biology (2021): 6736-6740.
27. Achilova, D. N. "SPECIFIC COURSE OF ALLERGIC REACTIONS IN CHILDREN." Web of Scientist: International Scientific Research Journal 2.09 (2021): 10-17.
28. Жумамуратова Б. С. ИЗУЧЕНИЕ ПРИЧИНЫ СМЕРТНОСТИ ОТ COVID-19 И КЛИНИКО-ЭПИДЕМИОЛОГИЧЕСКАЯ ОЦЕНКА //Барқарорлик ва Етақчи Тадқиқотлар онлайн илмий журналі. – 2022. – Т. 2. – №. 1. – С. 390-395.
29. Rajabturdieva Y. O. CHILDREN WITH ALLERGIC BRONCHIAL ASTHMA AND ATOPIC DERMATITIS IgA, IgM, IgG LEVELS //EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE. – 2021. – Т. 1. – №. 1. – С. 61-66.
30. Yomgurova O. R. ALLERGIC DISEASES IN INDUSTRIAL ZONES, IN THE POPULATION AROUND THE AFFECTED AREAS //Central Asian Journal of Medicine. – 2021. – Т. 2021. – №. 2. – С. 102-109.
31. Bakhadurova H. D., Akmalovna I. G. THE ROLE OF MULTIGENIC THROMBOPHILIA IN WOMEN WITH UNFAVORABLE OUTCOMES AFTER EXTRACORPOREAL FERTILIZATION //ResearchJet Journal of Analysis and Inventions. – 2022. – Т. 3. – №. 1. – С. 44-50.